期刊
AMERICAN JOURNAL OF THERAPEUTICS
卷 22, 期 4, 页码 298-317出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MJT.0000000000000103
关键词
cyclodextrins; sugammadex; rocuronium; vecuronium; muscle relaxant; muscle relaxant reversal; selective relaxant binding agents
资金
- Organon
- Schering/Plough
- Merck
Although neuromuscular block (NMB) allows immobility for airway management and surgical exposure, termination of its effect is limited by and associated with side effects of acetylcholinesterase inhibitors. Sugammadex is a selective relaxant binding agent that has been shown to reverse deep NMB, even when administered 3 minutes following a 1.2 mg/kg dose of rocuronium. This novel drug is a modified gamma cyclodextrin, that through encapsulation process terminates the effects of rocuronium and vecuronium (aminosteroid muscle relaxants), and enables the anesthesiologists rapidly to reverse profound NMB induced by rocuronium or vecuronium, in a can't ventilate, can't intubate crisis. In this review, data from published phase 1, 2, and 3 clinical trials are reviewed and presented. In addition, clinical trials on special patient populations (patients with pulmonary disease and renal insufficiency) are evaluated. Each article reviewed will conclude with a discussion of relevance, focus on adverse event profile, and clinical usefulness.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据